ARCELLX INC Stock Price, News & Analysis

Arcellx (NASDAQ: ACLX) reported third quarter 2025 results for the period ended September 30, 2025. Key financials: $576.0 million in cash, cash equivalents, and marketable securities; company expects these funds to support operations into 2028. Collaboration revenue fell to $4.9 million from $26.0 million, largely due to completion of dosing and manufacturing of anito-cel in iMMagine-1 in Q4 2024. R&D expense decreased to $35.1 million while G&A rose to $31.6 million. Net loss widened to $55.8 million from $25.9 million year-over-year.

Arcellx (NASDAQ: ACLX) will present updated clinical and preclinical data at the 67th ASH Annual Meeting (Dec 6-9, 2025) in Orlando. An oral presentation on iMMagine-1 (Phase 2 registrational study of anitocabtagene autoleucel) is scheduled for Dec 6, 2025 at 2:45 p.m. ET (publication #256).

The company said a more recent data cut will be shared, no delayed neurotoxicities (including Parkinsonism, cranial nerve palsies, Guillain-Barré, or immune effector cell-associated enterocolitis) have been observed to date, and a supplemental Blood publication on anito-cel’s D-Domain fast off-rate will appear in November 2025 (publication #7644). Arcellx reported a pre-BLA meeting with the FDA and reiterated a planned 2026 commercial launch.

Arcellx (NASDAQ:ACLX), a biotechnology company focused on innovative cell therapy and immunotherapies for cancer and incurable diseases, announced its upcoming participation in the 2025 Morgan Stanley Global Healthcare Conference.

The company's management will engage in a fireside chat on September 10, 2025 at 1:05 p.m. ET. Investors can access the live webcast through Arcellx's website, with a replay available for 30 days after the event.

Arcellx (NASDAQ: ACLX) reported Q2 2025 financial results and clinical progress. The company presented promising data from its Phase 2 pivotal iMMagine-1 study of anito-cel in relapsed/refractory multiple myeloma, showing a 97% overall response rate and 68% complete response rate among 117 patients.

Key clinical achievements include 93.3% minimal residual disease negativity in evaluable patients and strong survival rates, with no delayed neurotoxicities observed. The FDA cleared the IND application for ACLX-004 targeting CD33 and CD123.

Financially, Arcellx ended Q2 with $537.6 million in cash, expected to fund operations into 2028. The company reported a net loss of $52.8 million, with R&D expenses of $37.6 million and collaboration revenue of $7.6 million.

Arcellx (NASDAQ: ACLX), a biotechnology company focused on developing innovative cell therapy immunotherapies, has announced its participation in two upcoming investor events. The company will present at TD Cowen's 6th Annual Oncology Innovation Summit on May 27, 2025, at 9:00 a.m. PT in a virtual format. Additionally, Arcellx will host a management and physician presentation discussing the iMMagine-1 Pivotal Study Results during EHA2025 on June 13, 2025, at 8:30 p.m. CEST, both virtually and in-person in Milan, Italy. Both events will be accessible via webcast on the company's website and will remain available for 30 days after the events.

Arcellx (NASDAQ: ACLX) announced positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel) for relapsed/refractory multiple myeloma. The study, involving 117 patients with a median follow-up of 12.6 months, showed remarkable results: - 97% overall response rate (ORR) - 68% complete response/stringent complete response rate - 93.3% of evaluable patients achieved MRD negativity - 12-month progression-free survival rate of 78.8% - 12-month overall survival rate of 95.2% Notably, no delayed neurotoxicities or immune-mediated enterocolitis were observed. The therapy demonstrated efficacy in heavily pretreated patients, with 86% being triple refractory and 41% penta refractory. Arcellx, partnered with Kite (Gilead), plans for commercial launch in 2026.

Arcellx (NASDAQ: ACLX) reported its Q1 2025 financial results and business updates. The company's iMMagine-1 trial data has been accepted for oral presentation at the European Hematology Association Congress on June 14, 2025. A significant protocol update to the iMMagine-3 study now includes Minimal Residual Disease negativity as a dual primary endpoint alongside progression-free survival. The company strengthened its board with two new members: Andrew Galligan and Kristin Myers, bringing commercial and operational expertise. Financially, Arcellx reported $565.2 million in cash reserves, expected to fund operations into 2028. Q1 2025 results showed collaboration revenue of $8.1 million (down from $39.3M in Q1 2024), R&D expenses of $50.8 million (up from $32.3M), and a net loss of $62.3 million (compared to $7.2M loss in Q1 2024).

Arcellx (NASDAQ: ACLX) has appointed Andrew Galligan and Kristin Myers to its Board of Directors, while Derek Yoon steps down. The appointments come as the company prepares for potential commercialization in 2026.

Galligan, former CFO of Nevro Corp, brings over 30 years of strategic leadership experience, having driven commercial growth at multiple public companies. Myers, currently COO at Blue Cross Blue Shield Association, contributes 20+ years of healthcare expertise across payer, provider, and medtech sectors.

The appointments align with Arcellx's preparation for the anticipated commercial launch of anito-cel, their lead product candidate for relapsed or refractory multiple myeloma, through their partnership with Kite, a Gilead Company.

Arcellx (NASDAQ: ACLX) reported its Q4 and full-year 2024 financial results, highlighting significant progress in its anito-cel treatment for relapsed/refractory multiple myeloma (RRMM). The Phase 2 pivotal iMMagine-1 study showed impressive results with a 97% overall response rate and 62% complete response rate in 86 patients at 9.5 months median follow-up.

Key financial metrics include $625.7 million in cash and equivalents, providing runway into 2027. Q4 collaboration revenue was $15.3 million, down from $63.1 million in Q4 2023. Full-year net loss increased to $107.3 million from $70.7 million in 2023.

The company plans to commercially launch anito-cel in 2026 and will present updated iMMagine-1 data mid-2025. Notably, no delayed neurotoxicities were observed in 155 patients across Phase 1 and iMMagine-1 studies.